Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camoteskimab - Apollo Therapeutics

Next Previous
Drug Profile

Camoteskimab - Apollo Therapeutics

Alternative Names: AEVI-007; AVTX-007; CERC-007; MEDI 2338

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer Apollo Therapeutics; Avalo Therapeutics; MedImmune
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I/II Adult-onset Still's disease
  • Discontinued Chronic obstructive pulmonary disease; Multiple myeloma

Most Recent Events

  • 16 Sep 2025 Efficacy and adverse events data from a phase IIa trial in Atopic dermatitis released by Apollo Therapeutics
  • 01 May 2024 Phase-II clinical trials in Atopic dermatitis (Treatment-experienced) in Canada (IV) (NCT06436183)
  • 01 May 2024 Phase-II clinical trials in Atopic dermatitis (Treatment-experienced) in USA (IV) (NCT06436183)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top